Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia

References

• Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289 - 2301; PMID: 19474426; http://dx.doi.org/10.1056/NEJMoa0810069
   PubMed Web of Science ®Google Scholar
• Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23:900 - 904; PMID: 19262599; http://dx.doi.org/10.1038/leu.2009.37
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML MDS, MDS/MPN and AML. Leukemia 2009; 23:1343 - 1345; PMID: 19295549; http://dx.doi.org/10.1038/leu.2009.59
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41:838 - 842; PMID: 19483684; http://dx.doi.org/10.1038/ng.391
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113:6403 - 6410; PMID: 19372255; http://dx.doi.org/10.1182/blood-2009-02-205690
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, et al. Genetic characterization of TET1, TET2 and TET3 alterations in myeloid malignancies. Blood 2009; 114:144 - 147; PMID: 19420352; http://dx.doi.org/10.1182/blood-2009-03-210039
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. Groupe Francophone des Myélodysplasies. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009; 94:1676 - 1681; PMID: 19797729; http://dx.doi.org/10.3324/haematol.2009.011205
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324:930 - 935; PMID: 19372391; http://dx.doi.org/10.1126/science.1170116
   PubMed Web of Science ®Google Scholar
• Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5 hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466:1129 - 1133; PMID: 20639862; http://dx.doi.org/10.1038/nature09303
   PubMed Web of Science ®Google Scholar
• Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468:839 - 843; PMID: 21057493; http://dx.doi.org/10.1038/nature09586
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function and impair hematopoietic differentiation. Cancer Cell 2010; 18:553 - 567; PMID: 21130701; http://dx.doi.org/10.1016/j.ccr.2010.11.015
   PubMed Web of Science ®Google Scholar
• Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20:11 - 24; PMID: 21723200; http://dx.doi.org/10.1016/j.ccr.2011.06.001
   PubMed Web of Science ®Google Scholar
• Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20:25 - 38; PMID: 21723201; http://dx.doi.org/10.1016/j.ccr.2011.06.003
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079 - 2088; PMID: 9058730
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28:605 - 613; PMID: 20038729; http://dx.doi.org/10.1200/JCO.2009.23.4781
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Kato M, Kawahata R, Matsubara A, Takita J, et al. A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia 2011; 25:184 - 186; PMID: 20962861; http://dx.doi.org/10.1038/leu.2010.241
   PubMed Web of Science ®Google Scholar
• Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011; 25:877 - 879; PMID: 21339759; http://dx.doi.org/10.1038/leu.2011.10
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25:1153 - 1158; PMID: 21415852; http://dx.doi.org/10.1038/leu.2011.44
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al. Groupe Francophone des Myélodysplasies. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114:3285 - 3291; PMID: 19666869; http://dx.doi.org/10.1182/blood-2009-04-215814
   PubMed Web of Science ®Google Scholar
• Patsos G, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 2010; 126:1838 - 1849; PMID: 19795419
   PubMed Web of Science ®Google Scholar
• Zong RT, Das C, Tucker PW. Regulation of matrix attachment region-dependent, lymphocyte-restricted transcription through differential localization within promyelocytic leukemia nuclear bodies. EMBO J 2000; 19:4123 - 4133; PMID: 10921892; http://dx.doi.org/10.1093/emboj/19.15.4123
   PubMed Web of Science ®Google Scholar
• Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008; 40:1204 - 1210; PMID: 18758461; http://dx.doi.org/10.1038/ng.219
   PubMed Web of Science ®Google Scholar
• Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011; 473:343 - 348; PMID: 21490601; http://dx.doi.org/10.1038/nature10066
   PubMed Web of Science ®Google Scholar
• Wu H, D'Alessio AC, Ito S, Xia K, Wang Z, Cui K, et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011; 473:389 - 393; PMID: 21451524; http://dx.doi.org/10.1038/nature09934
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52 - 57; PMID: 16882708; http://dx.doi.org/10.1182/blood-2006-05-021162
   PubMed Web of Science ®Google Scholar
• Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 2006; 7:61 - 80; PMID: 16824020; http://dx.doi.org/10.1146/annurev.genom.7.080505.115630
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010; 24:1094 - 1096; PMID: 20376084; http://dx.doi.org/10.1038/leu.2010.52
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765 - 773; PMID: 19228619; http://dx.doi.org/10.1056/NEJMoa0808710
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424 - 2433; PMID: 21067377; http://dx.doi.org/10.1056/NEJMoa1005143
   PubMed Web of Science ®Google Scholar
• Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35:146 - 150; PMID: 12866414
   PubMed Web of Science ®Google Scholar
• Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem 2005; 77:504 - 510; PMID: 15649046; http://dx.doi.org/10.1021/ac0489420
   PubMed Web of Science ®Google Scholar
• Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009; 27:4002 - 4006; PMID: 19528370; http://dx.doi.org/10.1200/JCO.2009.22.6985
   PubMed Web of Science ®Google Scholar